Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
Moderna (0QF) Stock Price & Analysis
24 Followers
0QF Stock Chart & Stats
Day’s Range€97.24 - €102.22
52-Week Range― - ―
Previous Close€100.32
Volume16.00
Average Volume (3M)N/A
Market Cap
$38.57B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-€3.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€114.75Price Target Upside17.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Moderna News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ApprovalsNew cancer vaccine data shows a stronger Overall Survival (OS) trial in combination with PD1 compared to Keytruda alone, suggesting Moderna's treatment could be a significant advancement in cancer therapy.
Product Development And FundingModerna secures a funding agreement with Blackstone Life Sciences for up to $750 million to develop and commercialize the flu program, potentially reducing R&D costs and accelerating vaccine availability.
Vaccine EfficacyModerna's next-generation COVID-19 vaccine, mRNA-1283, demonstrates a higher immune response, indicating a potential improvement over existing vaccines, especially for populations over 65 years.
Bears Say
Financial PerformanceTop-line revenue growth has continued to decline, posing a challenging profit and loss backdrop as operating expenses remain high.
Future Growth ConcernsThere are concerns whether the company can achieve the $4B target in 2024 given that COVID revenue was mostly $3.7B in 2023.
Market CompetitionModerna's RSV vaccine faces an uphill battle as a third-to-market offering against two well capitalized pharma companies.
---
Options Prices
Currently, No data available
---
Ownership Overview
16.01% Insiders
20.13% Mutual Funds
22.42% Other Institutional Investors
41.43% Public Companies and
Individual Investors
0QF FAQ
What was Moderna’s price range in the past 12 months?
Currently, no data Available
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 02, 2024 which is in 6 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 22, 2024. The company reported €0.514 earnings per share for the quarter, beating the consensus estimate of -€0.922 by €1.435.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -€3.32.
How many shares outstanding does Moderna have?
Currently, no data Available
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of €0.514 in its last earnings report, beating expectations of -€0.922. Following the earnings report the stock price went up 10.152%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Flagship Pioneering Inc.. It holds Moderna’s shares valued at 961M.
---
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€114.75 (17.57% Upside)
€114.75 (17.57% Upside)
Blogger Sentiment
Neutral
DE:0QF Sentiment 54%
Sector Average 70%
Sector Average 70%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.20%
12-Months-Change
Fundamentals
Return on Equity
-28.59%
Trailing 12-Months
Asset Growth
-29.37%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
0QF Company Deck
---
0QF Earnings Call
Q4 2024
0:00 / 0:00
---
0QF Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
0QF Stock 12 Months Forecast
Average Price Target
€114.75
▲(17.57% Upside)
Technical Analysis
Best Analysts Covering 0QF
1 Year
1 Year Success Rate
24/25 ratings generated profit
1 Year Average Return
+269.93%
reiterated a buy rating 24 days ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +269.93% per trade.
---